Revvity (NYSE:RVTY – Get Rating) is one of 44 publicly-traded companies in the “Analytical instruments” industry, but how does it contrast to its rivals? We will compare Revvity to similar businesses based on the strength of its analyst recommendations, dividends, risk, profitability, valuation, institutional ownership and earnings.
Risk & Volatility
Revvity has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Revvity’s rivals have a beta of 1.03, indicating that their average stock price is 3% more volatile than the S&P 500.
Insider and Institutional Ownership
85.2% of Revvity shares are owned by institutional investors. Comparatively, 55.8% of shares of all “Analytical instruments” companies are owned by institutional investors. 0.5% of Revvity shares are owned by company insiders. Comparatively, 15.3% of shares of all “Analytical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
|Net Margins||Return on Equity||Return on Assets|
Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.2%. Revvity pays out 3.6% of its earnings in the form of a dividend. As a group, “Analytical instruments” companies pay a dividend yield of 0.4% and pay out 7.6% of their earnings in the form of a dividend.
This is a breakdown of current ratings for Revvity and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Analytical instruments” companies have a potential upside of 22.17%. Given Revvity’s rivals higher probable upside, analysts plainly believe Revvity has less favorable growth aspects than its rivals.
Valuation & Earnings
This table compares Revvity and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Revvity||$3.02 billion||$569.18 million||15.66|
|Revvity Competitors||$1.12 billion||-$234.91 million||-32.11|
Revvity has higher revenue and earnings than its rivals. Revvity is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Revvity beats its rivals on 9 of the 12 factors compared.
Revvity Company Profile
Revvity, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment consists of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.